Citius Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Citius Pharmaceuticals, Inc. (CTXR) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $10.84 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-23.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2025-12-23
- Citius Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.89M.
- Citius Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.72M, a 11.17% decline year-over-year.
- Citius Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-03-31 was $2.70M, a 12.23% decline year-over-year.
- Citius Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-12-31 was $2.52M, a 17.44% decline year-over-year.
- Citius Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.84M, a 8.47% decline from fiscal 2024.
- Citius Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $11.84M, a 78.94% increase from fiscal 2023.
- Citius Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $6.62M, a 69.40% increase from fiscal 2022.
- Citius Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $3.91M, a 168.45% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2025-09-30 | $2.89M derived: 10-K 12 month − 3 quarters · filed 2025-12-23 | $5.61M derived: sum of 2 quarters · filed 2025-12-23 | $8.31M derived: sum of 3 quarters · filed 2025-12-23 | $10.84M 10-K · filed 2025-12-23 | |
| 2025-06-30 | $2.72M 10-Q · filed 2025-08-12 | $5.42M derived: sum of 2 quarters · filed 2025-08-12 | $7.95M derived: sum of 3 quarters · filed 2025-08-12 | ||
| 2025-03-31 | $2.70M 10-Q · filed 2025-08-12 | $5.23M derived: sum of 2 quarters · filed 2025-08-12 | |||
| 2024-12-31 | $2.52M 10-Q · filed 2025-08-12 | ||||
| 2024-09-30 | $11.84M 10-K · filed 2025-12-23 | ||||
| 2024-06-30 | $3.06M 10-Q · filed 2025-08-12 | $6.14M derived: sum of 2 quarters · filed 2025-08-12 | $9.20M derived: sum of 3 quarters · filed 2025-08-12 | $12.27M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $3.08M 10-Q · filed 2025-08-12 | $3.08M 10-Q · filed 2024-08-12 | $9.21M derived: sum of 3 quarters · filed 2025-08-12 | $10.39M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2023-12-31 | $3.06M 10-Q · filed 2025-08-12 | $6.13M derived: sum of 2 quarters · filed 2025-08-12 | $7.31M derived: sum of 3 quarters · filed 2025-08-12 | $8.47M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2023-09-30 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-27 | $4.25M derived: sum of 2 quarters · filed 2024-12-27 | $5.42M derived: sum of 3 quarters · filed 2024-12-27 | $6.62M 10-K · filed 2024-12-27 | |
| 2023-06-30 | $1.17M 10-Q · filed 2024-08-12 | $2.34M derived: sum of 2 quarters · filed 2024-08-12 | $3.54M 10-Q · filed 2023-08-14 | $7.35M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $1.17M 10-Q · filed 2024-08-12 | $2.37M 10-Q · filed 2023-05-12 | $6.17M derived: sum of 3 quarters · filed 2024-08-12 | $6.21M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2022-12-31 | $1.20M 10-Q · filed 2024-08-12 | $5.01M derived: sum of 2 quarters · filed 2024-08-12 | $5.04M derived: sum of 3 quarters · filed 2024-08-12 | $5.08M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2022-09-30 | $3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-29 | $3.84M derived: sum of 2 quarters · filed 2023-12-29 | $3.87M derived: sum of 3 quarters · filed 2023-12-29 | $3.91M 10-K · filed 2023-12-29 | |
| 2022-06-30 | $33.33K 10-Q · filed 2023-08-14 | $1.00M 10-Q · filed 2022-08-11 | $66.67K derived: sum of 2 quarters · filed 2023-08-14 | $98.52K 10-Q · filed 2023-08-14 | |
| 2022-03-31 | $33.33K 10-Q · filed 2023-05-12 | $1.02M 10-Q · filed 2022-05-12 | $66.67K 10-Q · filed 2023-05-12 | ||
| 2021-12-31 | $904.60K 10-Q · filed 2023-02-10 | ||||
| 2021-09-30 | $1.45M 10-K · filed 2022-12-22 | ||||
| 2021-06-30 | $373.57K 10-Q · filed 2022-08-11 | $716.53K derived: sum of 2 quarters · filed 2022-08-11 | $993.11K derived: sum of 3 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $342.96K 10-Q · filed 2022-08-11 | $619.54K derived: sum of 2 quarters · filed 2022-08-11 | |||
| 2020-12-31 | $276.58K 10-Q · filed 2022-08-11 | ||||
| 2020-09-30 | $803.26K 10-K · filed 2021-12-15 | ||||
| 2020-06-30 | $175.01K 10-Q · filed 2021-08-12 | $333.84K derived: sum of 2 quarters · filed 2021-08-12 | $554.23K derived: sum of 3 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $158.83K 10-Q · filed 2021-08-12 | $379.22K derived: sum of 2 quarters · filed 2021-08-12 | |||
| 2019-12-31 | $220.38K 10-Q · filed 2021-08-12 | ||||
| 2019-09-30 | $715.98K 10-K · filed 2020-12-16 | ||||
| 2019-06-30 | $204.00K 10-Q · filed 2020-08-14 | $407.70K derived: sum of 2 quarters · filed 2020-08-14 | $578.95K derived: sum of 3 quarters · filed 2020-08-14 | ||
| 2019-03-31 | $203.69K 10-Q · filed 2020-08-14 | $374.94K derived: sum of 2 quarters · filed 2020-08-14 | |||
| 2018-12-31 | $171.25K 10-Q · filed 2020-08-14 | ||||
| 2018-06-30 | $124.40K 10-Q · filed 2019-08-14 | $339.06K derived: sum of 2 quarters · filed 2019-08-14 | $629.09K derived: sum of 3 quarters · filed 2019-08-14 | ||
| 2018-03-31 | $214.67K 10-Q · filed 2019-08-14 | $504.69K derived: sum of 2 quarters · filed 2019-08-14 | |||
| 2017-12-31 | $290.02K 10-Q · filed 2019-08-14 | ||||
| 2017-09-30 | $986.62K 10-K · filed 2019-12-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |